Abstract
The aim of this study was to describe biological features and aetiology of monoclonal gammopathy diagnosed during a 10-year period in the biochemistry department of the Moroccan Military Hospital Mohamed V in Rabat. The study was performed from 1 January 2000 to 31 December 2009. The records of 261 patients living in the Rabat area in which either serum protein electrophoresis and serum and/or urine immunofixation were performed at the biochemistry department of Military Instruction Hospital in Rabat were analysed. A cohort of 182 (70%) men and 79 (30%) women, the mean ± SD (range) ages were 60.21 ± 12.56 years. All patients were Caucasian. Electrophoresis found that 211 (80.84%) of the patients had a monoclonal gammopathy. Immunofixation confirmed that 251 (96.17%) patients had a monoclonal band in serum. In our cohort, MM was the most frequent diagnosis, our patients were late diagnosed.
This is a preview of subscription content, log in via an institution to check access.
References
Attaelmannan M, Levinson SS (2000) Understanding and identifying monoclonal gammopathies. Clin Chem 46:1230–1238
Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842–854
Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR et al (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362–1369
Ogmundsdottir HM, Haraldsdottir V, Johannesson G, Olafsdottir G, Bjamadottir K, Sigvaldason H et al (2002) Monoclonal gammopathy in Iceland: a population-based registry and follow-up. Br J Haematol 118:166–173
Landgren O, Gridley G, Turesson I et al (2006) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107(3):904–906 (Epub 2005 Oct 6)
Ola Landgren, S. Vincent Rajkumar et al (2007) Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 82(2):1468–1473
Kyle RA (1999) Sequence of testing for monoclonal gammopathies. Arch Pathol Lab Med 123:114–118
Groves FD, Travis LB, Devessa SS et al (1998) Waldenström’s macroglobulinemia: incidence patterns in the United States, 1988–1994. Cancer 82:1078–1081
Decaux O, Rodon P, Ruelland A, Estepa L, Leblay R, Grosbois B (2007) Epidemiology of monoclonal gammopathy in a general hospital, a university internal medicine department. Rev Med Interne 28:670–676
Iowa Surveillance, Epidemiology, and End-Results SEER Registry. 1973–1998
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7:585–598
Schwartzberg L (2007) Managed care considerations in the treatment of multiple myeloma. Managed Care Oncol 3:14–16, 47
Bradwell A (2006) Serum free light chain analysis, 4th edn. The Binding Site Ltd., Birmingham
Mseddi-Hdiji S, Haddouk S, BenAyed M, Tahri N, Elloumi M, Baklouti S, Hachicha J, Krichen MS, Bahloul Z, Masmoudi H (2005) Monoclonal gammapathies in Tunisia: epidemiological, immunochemical and etiological analysis of 288 cases. Pathol Biol 53:19–25
Tamimi W, Alaskar A, Alassiri M, Alsaeed W, Alarifi SA, Alenzi FQ et al (2010) Monoclonal gammopathy in a tertiary referral hospital. Clin Biochem 43:709–713
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ouzzif, Z., Doghmi, K., Bouhsain, S. et al. Monoclonal gammopathies in a Moroccan military hospital. Rheumatol Int 32, 3303–3307 (2012). https://doi.org/10.1007/s00296-011-2093-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-011-2093-6